Pub. Date : 2012
PMID : 23209813
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 2 | We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity in CRC. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 3 | In KRAS-wild-type CRC cells (COLO320DM), KRAS overexpression by mutant vectors caused excision repair cross-complementation group 1 (ERCC1) downregulation in protein and mRNA levels, and enhanced oxaliplatin sensitivity. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 4 | In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 5 | In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 6 | Overall, our findings suggest that KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells by the mechanism of ERCC1 downregulation. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |